Evofem Biosciences Says FDA Grants Fast Track Designation For EVO100 - Quick Facts

Biopharmaceutical company Evofem Biosciences, Inc. (EVFM) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women.

The Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.

Gonorrhoea is increasingly antibiotic-resistant and there are currently no FDA-approved prescription products to prevent gonorrhoea. There are 78 million sexually active woman in the U.S. potentially at risk of contracting sexually transmitted infections, including gonorrhoea.

Evofem's pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women, Evoguard, is currently enrolling 1,730 women in U.S. study sites. The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022.

Positive outcomes could support submission of a New Drug Application to the FDA for these potential indications by the end of 2022, with an anticipated PDUFA date in the third quarter of 2023 due to the expedited review afforded by the Fast Track designation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser. Archer Aviation, a developer of electric vertical take-off and landing or eVTOL aircraft, unveiled its autonomous electric two-seater aircraft, named "Maker", marking a milestone towards its commercial launch. The California-based air mobility company, which has already received orders from United Airlines, will use its inaugural aircraft prototype for testing as it works towards certification.
Follow RTT